According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
19h
GlobalData on MSNSanofi increases ownership stake partaking in pharma buyback trendThe French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Sanofi (NASDAQ:SNY – Free Report) by 25.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 314,180 shares of the company’s stock ...
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results